Who are Balance Tablet's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Magnesium sulfate administration, Intravenous magnesium sulfate infusion.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/balance-tablet.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Balance Tablet — Competitive Intelligence Brief

Balance Tablet (Balance Tablet) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Electrolyte/mineral supplement. Area: Nutritional/Metabolic support.

marketed Electrolyte/mineral supplement Nutritional/Metabolic support Small molecule Live · refreshed every 30 min

Target snapshot

Balance Tablet (Balance Tablet) — General Committee of Teaching Hospitals and Institutes, Egypt. Balance Tablet is a marketed formulation designed to support electrolyte and mineral balance, likely through provision of essential minerals and electrolytes.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Balance Tablet TARGET	Balance Tablet	General Committee of Teaching Hospitals and Institutes, Egypt	marketed	Electrolyte/mineral supplement
Magnesium sulfate administration	Magnesium sulfate administration	University of California, San Francisco	marketed	Electrolyte/mineral supplement; anticonvulsant	NMDA receptor; L-type calcium channel
Intravenous magnesium sulfate infusion	Intravenous magnesium sulfate infusion	Chinese University of Hong Kong	phase 3	Electrolyte/mineral supplement; anticonvulsant; vasodilator	NMDA receptor; L-type calcium channel

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Electrolyte/mineral supplement class)

General Committee of Teaching Hospitals and Institutes, Egypt · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Balance Tablet — Competitive Intelligence Brief. https://druglandscape.com/ci/balance-tablet. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab